Phase II Clinical Trial of PD-L1 in Combination with Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy with or Without Radiotherapy for Advanced Triple-negative Breast Cancer.

NCT06771609 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Advanced Triple-negative Breast Cancer

Interventions

DRUG: Adebry single antibody + VEX metronomic chemotherapy + radiotherapy
DRUG: debry single antibody + VEX metronomic chemotherapy

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences